Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

This is an open-label, randomized, single-center study. This translational study aims to explore tumor microenvironment remodelling after induction therapy lorlatinib and identify mechanisms of disease persistence and potential primary resistance mechanisms of lorlatinib as induction therapy treatment in surgically resectable ALK-rearranged NSCLC by single-cell RNA sequencing (scRNA-seq) and Spatial transcriptomics.

NCT Number	NCT06893354
Lead Sponsor	The First Affiliated Hospital of Guangzhou Medical University
Conditions	NSCLC
Enrollment	20 participants
Start Date	2025-05-10
Primary Completion	2027-07-20 (estimated)
Study Completion	2027-07-20 (estimated)
Updated on ClinicalTrials.gov	2025-03-25